ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy

A study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program has identified several features of kidney cancer tumours that influence their response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab. The research was conducted at the Dana-Farber Cancer Institute in America and is published in the journal, Nature Medicine. […]

read more

ASCO GU 2020: Adding radiotherapy to immunotherapy for the treatment of metastatic kidney cancer

Two clinical trials looking at the use of radiotherapy and immunotherapy for metastatic renal cell carcinoma (RCC) were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. First was the Phase II NIVES trial. In this trial, advanced kidney cancer patients who had been treated with targeted […]

read more

Ilixadencel improves responses and survival in metastatic kidney cancer

Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of  newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February. Ilixadencel is an immune primer designed to increase the body’s […]

read more

Scientists discover a part of the immune system that may be used to treat all cancers

Scientists from the University of Cardiff have discovered part of our immune system that could potentially be harnessed to treat all types of cancer. This potential treatment has not yet been tested in humans, but has been shown to kill prostate, breast, lung and other cancers in the laboratory. Researchers suggest that the treatment has […]

read more

Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more

Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

Cytoreductive nephrectomy offers survival benefit in metastatic kidney cancer

The results of a trial looking at immunotherapy treatment with and without cytoreductive nephrectomy were presented at the 20th annual meeting of the Society of Urologic Oncology in Washington this week. The study included 391 patients diagnosed with metastatic renal cell carcinoma (RCC) between 2015 and 2016 from the National Cancer Data Base (NCDB). Of […]

read more

IKCS 2019: Immune related adverse events

Dr Mehmet Asim Bilen of Emory University School of Medicine in Atlanta, USA led a session at the International Kidney Cancer Symposium (IKCS) last month on the diagnosis and management of immune-related toxicity. Immune-related adverse events occur in some patients who are taking immune checkpoint inhibitors for the treatment of advanced renal cell carcinoma (RCC). […]

read more

Liquid biopsies in the era of immuno-oncology

This review, published in the Annals of Oncology, discusses the role of liquid biopsies in the field of immuno-oncology to predict response, relapse or adverse events in cancer patients treated with immunotherapy. A liquid biopsy is a test done on a sample of blood to look for cancer cells from a tumour that are circulating […]

read more
Showing 1 to 10 of 32 results
  TOP